UPDATED 3:50 PM PT – Friday, October 30, 2020
‘Regeneron’ has paused its trials on the sickest patients following safety concerns.
According to reports on Friday, the pharmaceutical company decided to stop giving its antibody-drug to coronavirus patients on ventilators or those receiving high amounts of oxygen.
Announcing update on hospitalized #COVID19 patients in ongoing P2/3 study of Regeneron’s investigational antibody cocktail: https://t.co/6maNUOpruE pic.twitter.com/4xG0gg0qbT
— Regeneron (@Regeneron) October 30, 2020
However, the company has said it will continue the trial on patients with less severe bouts of the illness.
This comes as another pharmaceutical company, ‘Eli Lilly,’ ended trials on hospitalized patients on Monday after the drug was determined ineffective for severe cases of the coronavirus.
MORE NEWS: FBI Hiring Outside Contractor To Overhaul Use Of FISA Spying Tool
Be the first to comment